NDA 21721, held by Janssen Pharms. Levofloxacin.
As of Nov 16, 2026, NDA 21721 (Levaquin), held by Janssen Pharms, was first approved by FDA on Oct 21, 2004, with 26 approved supplements and 0 published complete response letters.
| Apr 27, 2012 | Supplement 28Efficacy (new indication or use) · Priority review | Approved | |
| May 5, 2008 | Supplement 15Efficacy (new indication or use) | Approved | |
| Sep 14, 2007 | Supplement 9Efficacy (new indication or use) | Approved | |
| Sep 11, 2007 | Supplement 11Efficacy (new indication or use) · Priority review | Approved | |
| Aug 4, 2005 | Supplement 2Efficacy (new indication or use) | Approved | |
| Nov 24, 2004 | Supplement 3Efficacy (new indication or use) · Priority review | Approved | |
| Oct 21, 2004 | Original applicationNew dosage form · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levaquin250MG/10ML · solution;oral | Levofloxacin | DiscontinuedReference drug |
| Feb 8, 2017 | Supplement 35Labeling · Standard review | Approved | |
| Jul 26, 2016 | Supplement 34Labeling · Standard review | Approved | |
| May 23, 2014 | Supplement 33Labeling · Standard review | Approved | |
| Aug 14, 2013 | Supplement 32Labeling | Approved | |
| Apr 27, 2012 | Supplement 28Efficacy (new indication or use) · Priority review | Approved | |
| Oct 11, 2011 | Supplement 31REMS | Approved | |
| Oct 11, 2011 | Supplement 29Labeling | Approved | |
| Jun 9, 2011 | Supplement 26Labeling · Standard review | Approved | |
| Feb 25, 2011 | Supplement 25Labeling | Approved | |
| Apr 27, 2009 | Supplement 21Labeling · Standard review | Approved | |
| Mar 12, 2009 | Supplement 22Labeling · Standard review | Approved | |
| Oct 3, 2008 | Supplement 20Labeling · Standard review | Approved | |
| May 5, 2008 | Supplement 15Efficacy (new indication or use) | Approved | |
| Apr 16, 2008 | Supplement 19Labeling · Standard review | Approved | |
| Dec 13, 2007 | Supplement 18Labeling · Standard review | Approved | |
| Nov 16, 2007 | Supplement 17Labeling · Standard review | Approved | |
| Nov 15, 2007 | Supplement 16Labeling · Standard review | Approved | |
| Sep 14, 2007 | Supplement 9Efficacy (new indication or use) | Approved | |
| Sep 11, 2007 | Supplement 11Efficacy (new indication or use) · Priority review | Approved | |
| Jun 19, 2007 | Supplement 13Labeling · Standard review | Approved | |
| May 31, 2007 | Supplement 10Labeling · Standard review | Approved | |
| May 10, 2007 | Supplement 12Labeling · Standard review | Approved | |
| Jun 23, 2006 | Supplement 7Labeling · Standard review | Approved | |
| Jan 20, 2006 | Supplement 6Labeling · Standard review | Approved | |
| Aug 4, 2005 | Supplement 2Efficacy (new indication or use) | Approved | |
| Nov 24, 2004 | Supplement 3Efficacy (new indication or use) · Priority review | Approved | |
| Oct 21, 2004 | Original applicationNew dosage form · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters